Remove 2026 Remove Compounding Remove Dosage
article thumbnail

Biopharmaceutical bioseparation systems market to value $20bn

European Pharmaceutical Review

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 percent CAGR between 2022 and 2026. According to recent market research , the global market for biopharmaceutical bioseparation systems, estimated to value $13 billion in 2022, is projected to grow to $19.6

Dosage 111
article thumbnail

Handling HPAPIs safely – what does it take?

European Pharmaceutical Review

” Highly potent APIs are pharmacologically and biologically active compounds at low doses. The compounds require special handling due to their cytotoxicity in the NCEs and investigational new drug applications (INDs). Managing highly potent cytotoxic compounds in early phases and at a late stage is a complex process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). mL, 3 mg/0.5 Hence, it needs to protect its patent as Trulicity patents are very vital to the company’s business as a whole.

article thumbnail

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

PharmaTech

It co-developed Comirnaty, the COVID-19 vaccine in partnership with Pfizer, and is gearing up for the commercial launch of its variant-adapted COVID-19 vaccine for the 2025/2026 season, pending regulatory approval. billion by 2034, exhibiting a compound average growth rate of 1.2% falciparum malaria. during 2025–2034 (26).

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Mary Dzhuryan is a class of 2026 PharmD candidate at the USC Alfred E. Mehrnaz Razavi Vakhshoori is a class of 2026 PharmD candidate at the USC Alfred E. The recent application was granted both priority review and orphan drug designation. Mann School of Pharmacy and Pharmaceutical Sciences in Los Angeles.